Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 19, 2020 3:16pm
245 Views
Post# 32147528

RE:RE:RE:RE:RE:This is a Joke

RE:RE:RE:RE:RE:This is a Joke
Ryeman40 wrote:

With this new nr I've changed my outlook with my previous notion that big pharma might wait. I was just trying to look at this from all angles even with stellar results. 
How long and how much money has been wasted on trying to develop a safe NSAID. Recent example was Gilead and their collaboration with Galapagos and a failed rheumatoid arthritis drug. I know Antibe is going with conservative numbers for sales but i believe they'll take away the market share from some of the top names and if big pharma gets a hold of 346 it will be at the top with all their extensive reach of hospitals, doctors and payors. If you were a doctor would you prescribe Naproxen which will damage your gut and takes up to 6 weeks for efficacy or 346 which has better efficacy, lower dose and extremely safe. 
Big pharma doesn't have to look anymore here it is. Somebody mentioned with the whole pipeline could be around 50 billion and i tend to agree. What would the market cap be? Haha a lot!
My price target is at least $40 for approval or buyout of 346. As of now thats around 1.6 billion market cap. Ridiculous really how cheap. Want the whole pipeline? Well thats going to cost you and rightfully so with years of revenues and breakthrough new safer drugs. 




Yes Ryeman.  I said $50B+
-----
We have now heard Dan use $30B for the first drug (includes other top indications to follow shortly after the first)
We also have an updated $11B for 352 which includes $9B for pill form and $3B for IV liquid form.
We also have $5B for 340 ... but ... that is a very old number and the future of this wonderdrug could lead to a very different number - if all goes well and if a new molecule strikes more life into the IP.
-----
That's a $46B market for 3 drugs and 340 could be higher.  IMO.


In terms of how quickly a deal comes ... tough call.
If ATE thinks a better deal is possible and Big Pharma wont pay a fair price, there may be a different partnership waiting in the wings.

Tough to call right now ... but ... I too would love to be taken out sooner than later ... at a very fair price.

: )
<< Previous
Bullboard Posts
Next >>